Merus N.V.

MRUS

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Petosemtamab	Phase 3	Head and Neck Squamous Cell Carcinoma	-
Investigator's Choice	Phase 3	Head and Neck Squamous Cell Carcinoma	-
MCLA-158	Phase 2	Advanced/Metastatic Solid Tumors	-
Zenocutuzumab	Phase 2	Breast Cancer Metastatic	-
MCLA-129	Phase 2	Non-Small Cell Lung Cancer Metastatic	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

March 2026~MCLA-129

Primary completion for MCLA-129 trial (NCT04868877) in Non-Small Cell Lung Cancer Metastatic

Regulatory Approvals

MRUS News